N-Nitrosodimethylamine investigations in Muta™Mouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations
Anthony M Lynch(Age UK), John W. Wills(Age UK), Charles F. McHugh(GlaxoSmithKline (United States)), Casey Kmett(Providence College), Julia Kenny(Age UK), Jonathan Howe(GlaxoSmithKline (United Kingdom)), James Harvey(GlaxoSmithKline (United Kingdom)), Mark Burman(Age UK), Deon Hildebrand(GlaxoSmithKline (United Kingdom)), Venkat Junnotula(Providence College), Wei Shi(Huazhong University of Science and Technology), Liangfu Chen(Sun Yat-sen University), Danielle S G Harte(Age UK), Kinnari K Patel(Providence College), Richard Haworth
Cited by 20
Related Papers
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
|Nature Cancer|2021|279
Improvement of in vivo genotoxicity assessment: Combination of acute tests and integration into standard toxicity testing
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2010|106
Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses
|Advanced Drug Delivery Reviews|2014|91
Follow‐up actions from positive results of in vitro genetic toxicity testing
|Environmental and Molecular Mutagenesis|2010|60